Psoriasis Clinical Trials in Los Angeles

Showing 61-80 of 174 trials

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

NCT04655313

This is a Phase 2, open label, maximal usage PK and safety study of ARQ-151 cream 0.3% in pediatric subjects (ages 6 to 11 years old) with plaque psoriasis:

PsoriasisPlaque Psoriasis

Arcutis Biotherapeutics, Inc.20 participantsStarted Nov 2020

Mountain Brook, Alabama, United States • Scottsdale, Arizona, United States • Fountain Valley, California, United States +14 more locations

COMPLETEDPhase 4< 1 mile

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.

NCT02425826

This study will evaluate the clinical efficacy, the patients quality of life, and safety of oral apremilast 30 mg twice daily (BID) compared to placebo, in adult patients with moderate plaque psoriasis during the 16 week Placebo controlled Phase and then upto 1 year in the Extension Phase of the trial.

Parapsoriasis

Amgen221 participantsStarted Apr 2015

Birmingham, Alabama, United States • Fremont, California, United States • Los Angeles, California, United States +23 more locations

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.

Psoriasis Trials in Other Cities

Effectiveness and Safety of BMS-986165 Compared to Placebo and Active Comparator in Participants With Psoriasis

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients

Vascular Inflammation in Psoriasis - Apremilast

Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis

A Study of LY3471851 in Participants With Psoriasis

Safety and Tolerability of Repeat Courses of IM Alefacept

Safety, Pharmacokinetics and Efficacy of ARQ-151 Cream in Adults With Mild to Moderate Chronic Plaque Psoriasis

Dose Ranging Study To Assess Efficacy, Safety and Tolerability Of PF-06700841 Topical Cream In Psoriasis

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

A Study of Mirikizumab in Participants With Plaque Psoriasis

Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis

Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque Psoriasis

MSB11022 in Moderate to Severe Chronic Plaque Psoriasis

Efficacy/Safety/Subject Satisfaction/Duration of Response of Clobetasol Propionate Spray vs Ointment in Plaque Psoriasis

Other Conditions in Los Angeles